title: Platelet-neutrophil interactions. (12S)-hydroxyeicosatetraen-1,20-dioic acid: a new eicosanoid synthesized by unstimulated neutrophils from (12S)-20-dihydroxyeicosatetraenoic acid.
abstract: In the course of a cell-cell interaction, 12-HETE (12-hydroxy-5,8,10,14-eicosatetraenoic acid), the arachidonic acid lipoxygenase product released from stimulated platelets, is metabolized by a cytochrome P-450 enzyme system in unstimulated neutrophils to 12,20-DiHETE (12,20-dihydroxy-5,8,10,14-eicosatetraenoic acid). This report describes time-dependent formation of a new eicosanoid by unstimulated neutrophils exposed to 12-HETE, which is more polar than 12,20-DiHETE (reversed-phase high performance liquid chromatography). Time course studies indicated that the precursor compound of this new eicosanoid was 12,20-DiHETE. This was determined by incubation of purified 12,20-DiHETE with neutrophils, which resulted in a progressive decrease in 12,20-DiHETE as formation of the polar metabolite increased. In the absence of neutrophils, 12,20-DiHETE was quantitatively unchanged. The new metabolite of 12,20-DiHETE was identified as 12-hydroxyeicosatetraen-1,20-dioic acid, based upon its UV spectrum, co-chromatography with a chemically synthesized standard in both high performance liquid chromatography and thin layer chromatography systems, and gas chromatography-mass spectrometry. Formation of 12-HETE-1,20-dioic acid was partially inhibited by 20-hydroxy-LTB4. This indicated that the neutrophil dehydrogenase responsible for further metabolism of 12,20-DiHETE may also be involved in conversion of 20-hydroxy-LTB4 to 20-carboxy-LTB4. The 12,20-DiHETE dehydrogenase enzyme system specifically requires NAD as cofactor and has subcellular components in both cytosolic and microsomal fractions which are synergistic in their activity. These results provide additional evidence for the occurrence of multicellular metabolic events during hemostasis, thrombosis, and the inflammatory response.
authors.affiliation: Department of Medicine, New York Veterans Administration Medical Center, New York 10010.
authors.forename: A J
authors.initials: AJ
authors.lastname: Marcus
authors.forename: L B
authors.initials: LB
authors.lastname: Safier
authors.forename: H L
authors.initials: HL
authors.lastname: Ullman
authors.forename: N
authors.initials: N
authors.lastname: Islam
authors.forename: M J
authors.initials: MJ
authors.lastname: Broekman
authors.forename: J R
authors.initials: JR
authors.lastname: Falck
authors.forename: S
authors.initials: S
authors.lastname: Fischer
authors.forename: C
authors.initials: C
authors.lastname: von Schacky
mesh_terms: D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / Q000031:analogs & derivatives; D001792:Blood Platelets / Q000166:cytology*; D002450:Cell Communication; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000097:blood*; D013058:Mass Spectrometry; D009243:NAD / Q000378:metabolism; D009504:Neutrophils / Q000166:cytology*; D013056:Spectrophotometry, Ultraviolet; D013997:Time Factors
chemical_list: C040735:12,20-dihydroxy-5,8,10,14-eicosatetraenoic acid; D006893:Hydroxyeicosatetraenoic Acids; D009243:NAD; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid